Hanmi Presents Promising Data on Muscle-Sparing Obesity Therapy

Hanmi Pharm presented promising preclinical data on its obesity treatment, HM17321, at the Obesity Society’s ObesityWeek conference. The treatment uses innovative AI and structural modeling to simultaneously reduce fat while preserving or even increasing muscle mass, addressing a key shortfall of traditional GLP-1-based obesity treatments, which often lead to muscle loss. Studies showed that HM17321, targeting the CRF2 receptor, promotes lipolysis and muscle function improvements, delivering weight loss comparable to semaglutide but with enhanced muscle preservation.

Hanmi also highlighted the effects of HM17321 in combination with its triple-action therapy, HM15275. Results showed that the combination was more effective in reducing fat mass while preserving lean muscle, enhancing the therapy’s potential for addressing metabolic health issues alongside obesity. As part of its comprehensive obesity research, Hanmi’s HM15275 showed substantial weight-loss potential in studies and is moving through clinical trials, with phase 2 trials expected to begin in 2025.